# Adam S Kibel

# List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/6915614/adam-s-kibel-publications-by-year.pdf

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

341	13,192	55	104
papers	citations	h-index	g-index
375	16,247 ext. citations	6	5.81
ext. papers		avg, IF	L-index

#	Paper	IF	Citations
341	PROTEUS: A randomized, double-blind, placebo (PBO)-controlled, phase 3 trial of apalutamide (APA) plus androgen deprivation therapy (ADT) versus PBO plus ADT prior to radical prostatectomy (RP) in patients (pts) with localized or locally advanced high-risk prostate cancer (PC) Journal of	2.2	O
340	Temporal changes in the screening, diagnosis and surgical treatment of genitourinary (GU) malignancies during the COVID-19 pandemic <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, 281-281	2.2	
339	Association between Operative Time and Short-Term Radical Cystectomy Complications <i>Urologia Internationalis</i> , <b>2022</b> , 1-7	1.9	
338	DNA Repair Pathways and Their Association With Lethal Prostate Cancer in African American and European American Men <i>JNCI Cancer Spectrum</i> , <b>2022</b> , 6, pkab097	4.6	1
337	Hormone Treatment of Prostate Cancer:: Evidence for Usage and Safety <i>Urologic Clinics of North America</i> , <b>2022</b> , 49, 309-321	2.9	O
336	loss overrides PARP inhibitor sensitivity driven by loss in prostate cancer <i>Science Advances</i> , <b>2022</b> , 8, eabl9794	14.3	0
335	Epidemiology and Prevention of Prostate Cancer. European Urology Oncology, 2021,	6.7	20
334	Insulinemic and Inflammatory Dietary Patterns and Risk of Prostate Cancer. <i>European Urology</i> , <b>2021</b> , 79, 405-412	10.2	5
333	EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer. <i>Nature Cancer</i> , <b>2021</b> , 2, 444-456	15.4	37
332	Evaluation of a Multiethnic Polygenic Risk Score Model for Prostate Cancer. <i>Journal of the National Cancer Institute</i> , <b>2021</b> ,	9.7	3
331	KLK3 SNP-SNP interactions for prediction of prostate cancer aggressiveness. <i>Scientific Reports</i> , <b>2021</b> , 11, 9264	4.9	3
330	Reply by Authors. <i>Journal of Urology</i> , <b>2021</b> , 205, 1274	2.5	
329	One-year urinary and sexual outcome trajectories among prostate cancer patients treated by radical prostatectomy: a prospective study. <i>BMC Urology</i> , <b>2021</b> , 21, 81	2.2	O
328	A Selective Androgen Receptor Modulator (OPK-88004) in Prostate Cancer Survivors: A Randomized Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2021</b> , 106, 2171-2186	5.6	2
327	Systematic Review of Time to Definitive Treatment for Intermediate Risk and High Risk Prostate Cancer: Are Delays Associated with Worse Outcomes?. <i>Journal of Urology</i> , <b>2021</b> , 205, 1263-1274	2.5	2
326	Effect of Medicaid Expansion on Receipt of Definitive Treatment and Time to Treatment Initiation by Racial and Ethnic Minorities and at Minority-Serving Hospitals: A Patient-Level and Facility-Level Analysis of Breast, Colon, Lung, and Prostate Cancer. <i>JCO Oncology Practice</i> , <b>2021</b> , 17, e654-e665	2.3	1
325	Is Medicaid expansion associated with increases in palliative treatments for metastatic cancer?. <i>Journal of Comparative Effectiveness Research</i> , <b>2021</b> , 10, 733-741	2.1	O

324	Domain adaptation for segmentation of critical structures for prostate cancer therapy. <i>Scientific Reports</i> , <b>2021</b> , 11, 11480	4.9	O
323	Impact of high-intensity local treatment on overall survival in stage IV upper tract urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2021</b> , 39, 436.e1-436.e10	2.8	1
322	Workplace absenteeism amongst patients undergoing open vs. robotic radical prostatectomy, hysterectomy, and partial colectomy. <i>Surgical Endoscopy and Other Interventional Techniques</i> , <b>2021</b> , 35, 1644-1650	5.2	О
321	Metabolomics of Prostate Cancer Gleason Score in Tumor Tissue and Serum. <i>Molecular Cancer Research</i> , <b>2021</b> , 19, 475-484	6.6	7
320	Racial and Ethnic Variation in PSA Testing and Prostate Cancer Incidence Following the 2012 USPSTF Recommendation. <i>Journal of the National Cancer Institute</i> , <b>2021</b> , 113, 719-726	9.7	18
319	Access denied: The relationship between patient insurance status and access to high-volume hospitals. <i>Cancer</i> , <b>2021</b> , 127, 577-585	6.4	4
318	Health care spending in prostate cancer: An assessment of characteristics and health care utilization of high resource-patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2021</b> , 39, 130.e17-130.e24	2.8	1
317	The impact of smoking on radical cystectomy complications increases in elderly patients. <i>Cancer</i> , <b>2021</b> , 127, 1387-1394	6.4	1
316	African-specific improvement of a polygenic hazard score for age at diagnosis of prostate cancer. <i>International Journal of Cancer</i> , <b>2021</b> , 148, 99-105	7.5	7
315	Risk of Dementia and Depression in Young and Middle-aged Men Presenting with Nonmetastatic Prostate Cancer Treated with Androgen Deprivation Therapy. <i>European Urology Oncology</i> , <b>2021</b> , 4, 66-7	72 <sup>6.7</sup>	9
314	Sex-specific Differences in the Quality of Treatment of Muscle-invasive Bladder Cancer Do Not Explain the Overall Survival Discrepancy. <i>European Urology Focus</i> , <b>2021</b> , 7, 124-131	5.1	16
313	Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. <i>Nature Genetics</i> , <b>2021</b> , 53, 65-75	36.3	62
312	Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2021</b> , 24, 532-541	6.2	3
311	Polygenic hazard score is associated with prostate cancer in multi-ethnic populations. <i>Nature Communications</i> , <b>2021</b> , 12, 1236	17.4	14
310	Delay in surgery for cT1b-2 kidney cancer beyond 90 days is associated with poorer survival: implications for prioritization during the COVID-19 pandemic. <i>Minerva Urology and Nephrology</i> , <b>2021</b> , 73, 404-406	2.3	О
309	Adverse Histopathologic Characteristics in Small Papillary Renal Cell Carcinomas Have Minimal Impact on Prognosis. <i>American Journal of Clinical Pathology</i> , <b>2021</b> , 156, 550-558	1.9	
308	Impact of Pathogenic Germline DNA Damage Repair alterations on Response to Intense Neoadjuvant Androgen Deprivation Therapy in High-risk Localized Prostate Cancer. <i>European Urology</i> , <b>2021</b> , 80, 295-303	10.2	6
307	Cyclophosphamide-associated bladder cancers and considerations for survivorship care: A systematic review. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2021</b> , 39, 678-685	2.8	O

306	Recovery from minimally invasive vs. open surgery in kidney cancer patients: Opioid use and workplace absenteeism. <i>Investigative and Clinical Urology</i> , <b>2021</b> , 62, 56-64	1.9	1
305	The Variant C.349A>G Is Associated with Prostate Cancer Risk and Carriers Share a Common Ancestor. <i>Cancers</i> , <b>2020</b> , 12,	6.6	4
304	Geographic Distribution of Racial Differences in Prostate Cancer Mortality. <i>JAMA Network Open</i> , <b>2020</b> , 3, e201839	10.4	17
303	A Germline Variant at 8q24 Contributes to Familial Clustering of Prostate Cancer in Men of African Ancestry. <i>European Urology</i> , <b>2020</b> , 78, 316-320	10.2	13
302	The effect of sample size on polygenic hazard models for prostate cancer. <i>European Journal of Human Genetics</i> , <b>2020</b> , 28, 1467-1475	5.3	5
301	Delayed blood transfusion is associated with mortality following radical cystectomy. <i>Scandinavian Journal of Urology</i> , <b>2020</b> , 54, 290-296	1.6	1
300	A Genetic Risk Score to Personalize Prostate Cancer Screening, Applied to Population Data. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2020</b> , 29, 1731-1738	4	14
299	miR-218 Expressed in Endothelial Progenitor Cells Contributes to the Development and Repair of the Kidney Microvasculature. <i>American Journal of Pathology</i> , <b>2020</b> , 190, 642-659	5.8	7
298	Effect of a Behavioral Intervention to Increase Vegetable Consumption on Cancer Progression Among Men With Early-Stage Prostate Cancer: The MEAL Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2020</b> , 323, 140-148	27.4	20
297	Assessment of Out-of-Pocket Costs for Robotic Cancer Surgery in US Adults. <i>JAMA Network Open</i> , <b>2020</b> , 3, e1919185	10.4	6
296	Alvimopan Is Associated With a Reduction in Length of Stay and Hospital Costs for Patients Undergoing Radical Cystectomy. <i>Urology</i> , <b>2020</b> , 140, 115-121	1.6	1
295	Results of a phase II trial of intense androgen deprivation therapy prior to radical prostatectomy (RP) in men with high-risk localized prostate cancer (PC) <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 5503-55	6 <del>32</del>	7
294	PROTEUS: A randomized, double-blind, placebo (PBO)-controlled, phase III trial of apalutamide (APA) plus androgen deprivation therapy (ADT) versus PBO plus ADT prior to radical prostatectomy (RP) in patients with localized high-risk or locally advanced prostate cancer (PC) Journal of Clinical	2.2	2
293	Oncology, <b>2020</b> , 38, TPS383-TPS383 5-alpha reductase inhibitors (5-ARI) and prostate cancer mortality among men with regular access to screening and health care <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 39-39	2.2	
292	Impact of MRI on outcomes in active surveillance (AS) for localized prostate cancer in a hospital registry <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 280-280	2.2	
291	Mobile Health App for Prostate Cancer Patients on Androgen Deprivation Therapy: Qualitative Usability Study. <i>JMIR MHealth and UHealth</i> , <b>2020</b> , 8, e20224	5.5	3
<b>29</b> 0	Rease of the MonthPfrom Brigham and WomenB Hospital, Boston, MA, USA: a 70-year-old man with lung cysts and bilateral renal masses. <i>BJU International</i> , <b>2020</b> , 126, 428-432	5.6	
289	Predictors of Recurrence, and Progression-Free and Overall Survival following Open versus Robotic Radical Cystectomy: Analysis from the RAZOR Trial with a 3-Year Followup. <i>Journal of Urology</i> , <b>2020</b> , 203, 522-529	2.5	31

# (2019-2020)

288	Trends in Adherence to Thromboprophylaxis Guideline in Patients Undergoing Radical Cystectomy. <i>Urology</i> , <b>2020</b> , 135, 44-49	1.6	4
287	The impact of underinsurance on bladder cancer diagnosis, survival, and care delivery for individuals under the age of 65´years. <i>Cancer</i> , <b>2020</b> , 126, 496-505	6.4	9
286	Minimally invasive cancer surgery is associated with a lower risk of venous thromboembolic events. Journal of Surgical Oncology, <b>2020</b> , 121, 578-583	2.8	2
285	Delayed nephrectomy has comparable long-term overall survival to immediate nephrectomy for cT1a renal cell carcinoma: A population-based analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2020</b> , 38, 74.e13-74.e20	2.8	4
284	Facility-Level Variation in Pelvic Lymphadenectomy During Radical Prostatectomy and Effect on Overall Survival in Men with High-Risk Prostate Cancer. <i>Annals of Surgical Oncology</i> , <b>2020</b> , 27, 1929-193	6 <sup>3.1</sup>	2
283	Clinical Utility of a Genomic Classifier in Men Undergoing Radical Prostatectomy: The PRO-IMPACT Trial. <i>Practical Radiation Oncology</i> , <b>2020</b> , 10, e82-e90	2.8	7
282	Differences in survival and impact of adjuvant chemotherapy in patients with variant histology of tumors of the renal pelvis. <i>World Journal of Urology</i> , <b>2020</b> , 38, 2227-2236	4	7
281	Risk of dementia following androgen deprivation therapy for treatment of prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2020</b> , 23, 410-418	6.2	9
280	Risk factors and reasons for reoperation after radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2020</b> , 38, 269-277	2.8	6
279	Association of surgical approach and prolonged opioid prescriptions in patients undergoing major pelvic cancer procedures. <i>BMC Surgery</i> , <b>2020</b> , 20, 235	2.3	1
278	EDITORIAL COMMENT. <i>Urology</i> , <b>2020</b> , 139, 42-43	1.6	
277	AUTHOR REPLY. <i>Urology</i> , <b>2020</b> , 140, 121	1.6	
276	Implementation of a Perioperative Venous Thromboembolism Prophylaxis Program for Patients Undergoing Radical Cystectomy on an Enhanced Recovery After Surgery Protocol. <i>European Urology Focus</i> , <b>2020</b> , 6, 74-80	5.1	5
275	Contemporary national trends in prostate cancer risk profile at diagnosis. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2020</b> , 23, 81-87	6.2	16
274	Quantifying the Overall Survival Benefit With Early Radical Cystectomy for Patients With Histologically Confirmed T1 Non-muscle-invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , <b>2020</b> , 18, e651-e659	3.3	4
273	Assessment of Time-to-Treatment Initiation and Survival in a Cohort of Patients With Common Cancers. <i>JAMA Network Open</i> , <b>2020</b> , 3, e2030072	10.4	17
272	Shared heritability and functional enrichment across six solid cancers. <i>Nature Communications</i> , <b>2019</b> , 10, 431	17.4	45
271	Contemporary Survival Rates for Muscle-Invasive Bladder Cancer Treated With Definitive or Non-Definitive Therapy. <i>Clinical Genitourinary Cancer</i> , <b>2019</b> , 17, e488-e493	3.3	6

270	Comparing Long-Term Outcomes Following Radical and Partial Nephrectomy for cT1 Renal Cell Carcinoma in Young and Healthy Individuals. <i>JNCI Cancer Spectrum</i> , <b>2019</b> , 3, pkz003	4.6	5
269	Association of Care at Minority-Serving vs Non-Minority-Serving Hospitals With Use of Palliative Care Among Racial/Ethnic Minorities With Metastatic Cancer in the United States. <i>JAMA Network Open</i> , <b>2019</b> , 2, e187633	10.4	22
268	The association of marital status and mortality among men with early-stage prostate cancer treated with radical prostatectomy: insight into post-prostatectomy survival strategies. <i>Cancer Causes and Control</i> , <b>2019</b> , 30, 871-876	2.8	11
267	Comparison of Hospital Readmission After Total Hip and Total Knee Arthroplasty vs Spinal Surgery After Implementation of the Hospital Readmissions Reduction Program. <i>JAMA Network Open</i> , <b>2019</b> , 2, e194634	10.4	17
266	The current landscape of low-value care in men diagnosed with prostate cancer: what is the role of individual hospitals?. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2019</b> , 37, 575.e9-575.e18	2.8	3
265	Prostate cancer in the medicare shared savings program: are Accountable Care Organizations associated with reduced expenditures for men with prostate cancer?. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2019</b> , 22, 593-599	6.2	5
264	Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without Abiraterone. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 923-9	93 <sup>2</sup> 1 <sup>2</sup>	42
263	Contemporary perceptions of human papillomavirus and penile cancer: Perspectives from a national survey. <i>Canadian Urological Association Journal</i> , <b>2019</b> , 13, 32-37	1.2	2
262	Variation in Positive Surgical Margin Status After Radical Prostatectomy for pT2 Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , <b>2019</b> , 17, e1060-e1068	3.3	6
261	Recommended Cancer Screening in Accountable Care Organizations: Trends in Colonoscopy and Mammography in the Medicare Shared Savings Program. <i>Journal of Oncology Practice</i> , <b>2019</b> , 15, e547-e	5 <del>3</del> 9	5
260	Selective targeting of PARP-2 inhibits androgen receptor signaling and prostate cancer growth through disruption of FOXA1 function. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2019</b> , 116, 14573-14582	11.5	32
259	Adoption of immunotherapy in the community for patients diagnosed with metastatic melanoma <b>2019</b> , 7, 289		9
258	Comparing the Association Between Insurance and Mortality in Ovarian, Pancreatic, Lung, Colorectal, Prostate, and Breast Cancers. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2019</b> , 17, 1049-1058	7.3	14
257	PROTEUS: A randomized, double-blind, placebo (PBO)-controlled, phase 3 trial of apalutamide (APA) plus androgen deprivation therapy (ADT) versus PBO plus ADT prior to radical prostatectomy (RP) in patients with localized high-risk or locally advanced prostate cancer (PC) <i>Journal of Clinical</i>	2.2	3
256	Quality of Care in the Treatment of Localized Intermediate and High Risk Prostate Cancer at Minority Serving Hospitals. <i>Journal of Urology</i> , <b>2019</b> , 201, 735-741	2.5	16
255	Impact of Accountable Care Organizations on Prostate Cancer Screening and Biopsies in the United States. <i>Urology Practice</i> , <b>2019</b> , 6, 159-164	0.8	1
254	Facility Level Variation in Rates of Definitive Therapy for Low Risk Prostate Cancer in Men with Limited Life Expectancy: An Opportunity for Value Based Care Redesign. <i>Journal of Urology</i> , <b>2019</b> , 201, 728-734	2.5	4
253	Adverse Histopathologic Characteristics in Small Clear Cell Renal Cell Carcinomas Have Negative Impact on Prognosis: A Study of 631 Cases With Clinical Follow-up. <i>American Journal of Surgical Pathology</i> , <b>2019</b> , 43, 1413-1420	6.7	3

252	Multilevel Analysis of Readmissions After Radical Cystectomy for Bladder Cancer in the USA: Does the Hospital Make a Difference?. <i>European Urology Oncology</i> , <b>2019</b> , 2, 349-354	6.7	5
251	Baseline Prostate-specific Antigen Level in Midlife and Aggressive Prostate Cancer in Black Men. <i>European Urology,</i> <b>2019</b> , 75, 399-407	10.2	23
250	Targeting the MIF/CXCR7/AKT Signaling Pathway in Castration-Resistant Prostate Cancer. <i>Molecular Cancer Research</i> , <b>2019</b> , 17, 263-276	6.6	15
249	Evaluation of the contribution of demographics, access to health care, treatment, and tumor characteristics to racial differences in survival of advanced prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2019</b> , 22, 125-136	6.2	29
248	Neoadjuvant Androgen Deprivation Therapy Prior to Radical Prostatectomy: Recent Trends in Utilization and Association with Postoperative Surgical Margin Status. <i>Annals of Surgical Oncology</i> , <b>2019</b> , 26, 297-305	3.1	17
247	Evaluating the cost of surveillance for non-muscle-invasive bladder cancer: an analysis based on risk categories. <i>World Journal of Urology</i> , <b>2019</b> , 37, 2059-2065	4	19
246	Comparative Effectiveness of Radical Prostatectomy Versus External Beam Radiation Therapy Plus Brachytherapy in Patients with High-risk Localized Prostate Cancer. <i>European Urology</i> , <b>2019</b> , 75, 552-55	5 <sup>10.2</sup>	29
245	Impact of adjuvant chemotherapy in patients with adverse features and variant histology at radical cystectomy for muscle-invasive carcinoma of the bladder: Does histologic subtype matter?. <i>Cancer</i> , <b>2019</b> , 125, 1449-1458	6.4	28
244	Impact of tumor, treatment, and access on outcomes in bladder cancer: Can equal access overcome race-based differences in survival?. <i>Cancer</i> , <b>2019</b> , 125, 1319-1329	6.4	6
243	Re: Association of Robotic-Assisted vs Laparoscopic Radical Nephrectomy with Perioperative Outcomes and Health Care Costs, 2003 to 2015. <i>European Urology</i> , <b>2019</b> , 75, 696-697	10.2	
242	Circulating Metabolic Biomarkers of Screen-Detected Prostate Cancer in the ProtecT Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2019</b> , 28, 208-216	4	9
241	Levels and patterns of self-reported and objectively-measured free-living physical activity among prostate cancer survivors: A prospective cohort study. <i>Cancer</i> , <b>2019</b> , 125, 798-806	6.4	11
240	Examining the relationship between complications and perioperative mortality following radical cystectomy: a population-based analysis. <i>BJU International</i> , <b>2019</b> , 124, 40-46	5.6	7
239	Liver Disease in Men Undergoing Androgen Deprivation Therapy for Prostate Cancer. <i>Journal of Urology</i> , <b>2018</b> , 200, 573-581	2.5	19
238	Current Staging Strategies for Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Cell Carcinoma. <i>Urologic Clinics of North America</i> , <b>2018</b> , 45, 143-154	2.9	8
237	The effect of treatment at minority-serving hospitals on outcomes for bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2018</b> , 36, 238.e7-238.e17	2.8	11
236	Reassessing the value of high-volume cancer care in the era of precision medicine. <i>Cancer</i> , <b>2018</b> , 124, 1319-1321	6.4	15
235	Cognitive Impairment in Men with Prostate Cancer Treated with Androgen Deprivation Therapy: A Systematic Review and Meta-Analysis. <i>Journal of Urology</i> , <b>2018</b> , 199, 1417-1425	2.5	52

234	Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2018</b> , 21, 364-372	6.2	29
233	The association of weight change in young adulthood and smoking status with risk of prostate cancer recurrence. <i>International Journal of Cancer</i> , <b>2018</b> , 142, 2011-2018	7.5	2
232	Comparative effectiveness of robot-assisted vs. open radical cystectomy. <i>Urologic Oncology:</i> Seminars and Original Investigations, <b>2018</b> , 36, 88.e1-88.e9	2.8	35
231	Editorial Comment. <i>Journal of Urology</i> , <b>2018</b> , 199, 712	2.5	
230	Factors Influencing Prostate Specific Antigen Testing in the United States. <i>Urology Practice</i> , <b>2018</b> , 5, 43	8 <del>4</del> 83	О
229	Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts. <i>BMJ, The</i> , <b>2018</b> , 360, j5757	5.9	85
228	Associations of specific postoperative complications with costs after radical cystectomy. <i>BJU International</i> , <b>2018</b> , 121, 428-436	5.6	23
227	Effects of Androgen Deprivation Therapy on Pain Perception, Quality of Life, and Depression in Men With Prostate Cancer. <i>Journal of Pain and Symptom Management</i> , <b>2018</b> , 55, 307-317.e1	4.8	15
226	Adjuvant Chemotherapy vs Observation for Patients With Adverse Pathologic Features at Radical Cystectomy Previously Treated With Neoadjuvant Chemotherapy. <i>JAMA Oncology</i> , <b>2018</b> , 4, 225-229	13.4	42
225	Variation in the use of active surveillance for low-risk prostate cancer. <i>Cancer</i> , <b>2018</b> , 124, 55-64	6.4	26
224	Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial. <i>Lancet, The</i> , <b>2018</b> , 391, 2525-2536	40	314
223	Functional roles and potential clinical application of miRNA-345-5p in prostate cancer. <i>Prostate</i> , <b>2018</b> , 78, 927-937	4.2	27
222	Antigen-Specific CD8 Lytic Phenotype Induced by Sipuleucel-T in Hormone-Sensitive or Castration-Resistant Prostate Cancer and Association with Overall Survival. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 4662-4671	12.9	15
221	Characterizing trends in treatment modalities for localized muscle-invasive bladder cancer in the pre-immunotherapy era. <i>World Journal of Urology</i> , <b>2018</b> , 36, 1767-1774	4	9
220	AA9int: SNP interaction pattern search using non-hierarchical additive model set. <i>Bioinformatics</i> , <b>2018</b> , 34, 4141-4150	7.2	3
219	Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. <i>Nature Genetics</i> , <b>2018</b> , 50, 928-936	36.3	340
218	Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. <i>Nature Communications</i> , <b>2018</b> , 9, 2256	17.4	57
217	Impact of adequate pelvic lymph node dissection on overall survival after radical cystectomy: A stratified analysis by clinical stage and receipt of neoadjuvant chemotherapy. <i>Urologic Oncology:</i> Seminars and Original Investigations, <b>2018</b> , 36, 78.e13-78.e19	2.8	11

#### (2017-2018)

216	Racial Disparity in Delivering Definitive Therapy for Intermediate/High-risk Localized Prostate Cancer: The Impact of Facility Features and Socioeconomic Characteristics. <i>European Urology</i> , <b>2018</b> , 73, 445-451	10.2	27	
215	Variations in the Costs of Radical Cystectomy for Bladder Cancer in the USA. <i>European Urology</i> , <b>2018</b> , 73, 374-382	10.2	42	
214	Germline variation at 8q24 and prostate cancer risk in men of European ancestry. <i>Nature Communications</i> , <b>2018</b> , 9, 4616	17.4	30	
213	The impact of age at the time of radiotherapy for localized prostate cancer on the development of second primary malignancies. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2018</b> , 36, 500.e11	- <del>3</del> 00.e	19	
212	Use of Preventive Health Services Among Cancer Survivors in the U.S. <i>American Journal of Preventive Medicine</i> , <b>2018</b> , 55, 830-838	6.1	6	
211	Mechanisms responsible for reduced erythropoiesis during androgen deprivation therapy in men with prostate cancer. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , <b>2018</b> , 315, E1185-	E1193	15	
210	Androgen Deprivation Therapy Is Associated With Prolongation of QTc Interval in Men With Prostate Cancer. <i>Journal of the Endocrine Society</i> , <b>2018</b> , 2, 485-496	0.4	26	
209	Contemporary trends in the utilisation of radical prostatectomy. <i>BJU International</i> , <b>2018</b> , 122, 726-728	5.6	3	
208	Heterogeneity in Definitions of High-risk Prostate Cancer and Varying Impact on Mortality Rates after Radical Prostatectomy. <i>European Urology Oncology</i> , <b>2018</b> , 1, 143-148	6.7	12	
207	30-Day Adverse Events Following Cystectomy for Bladder Cancer Versus Benign Bladder Conditions. <i>Urology Practice</i> , <b>2017</b> , 4, 388-394	0.8	2	
206	A Nationwide Survey of Prostate Specific Antigen Based Screening and Counseling for Prostate Cancer. <i>Urology Practice</i> , <b>2017</b> , 4, 210-217	0.8	0	
205	Effectiveness of Adjuvant Chemotherapy After Radical Nephroureterectomy for Locally Advanced and/or Positive Regional Lymph Node Upper Tract Urothelial Carcinoma. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 852-860	2.2	79	
204	Prophylactic Antibiotics and Postoperative Complications of Radical Cystectomy: A Population Based Analysis in the United States. <i>Journal of Urology</i> , <b>2017</b> , 198, 297-304	2.5	25	
203	Pathologic correlation of transperineal in-bore 3-Tesla magnetic resonance imaging-guided prostate biopsy samples with radical prostatectomy specimen. <i>Abdominal Radiology</i> , <b>2017</b> , 42, 2154-215	59	5	
202	Androgen receptor-regulated miRNA-193a-3p targets AJUBA to promote prostate cancer cell migration. <i>Prostate</i> , <b>2017</b> , 77, 1000-1011	4.2	25	
201	Decipher test impacts decision making among patients considering adjuvant and salvage treatment after radical prostatectomy: Interim results from the Multicenter Prospective PRO-IMPACT study. <i>Cancer</i> , <b>2017</b> , 123, 2850-2859	6.4	44	
200	Comparative Effectiveness of Trimodal Therapy Versus Radical Cystectomy for Localized Muscle-invasive Urothelial Carcinoma of the Bladder. <i>European Urology</i> , <b>2017</b> , 72, 483-487	10.2	65	
199	Neoadjuvant Enzalutamide Prior to Prostatectomy. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 2169-2176	12.9	50	

198	Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men with Hormone-Sensitive Biochemically Recurrent Prostate Cancer: A Phase II Randomized Trial. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 2451-2459	12.9	48
197	Association Between Combined TMPRSS2:ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer. <i>JAMA Oncology</i> , <b>2017</b> , 3, 1085-1093	13.4	88
196	Morbidity and Mortality of Locally Advanced Prostate Cancer: A Population Based Analysis Comparing Radical Prostatectomy versus External Beam Radiation. <i>Journal of Urology</i> , <b>2017</b> , 198, 1061-	1058	26
195	The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer. <i>Cancer</i> , <b>2017</b> , 123, 3532-3539	6.4	147
194	Resident Involvement in Radical Inguinal Orchiectomy for Testicular Cancer Does Not Adversely Impact Perioperative Outcomes - A Retrospective Study. <i>Urologia Internationalis</i> , <b>2017</b> , 98, 472-477	1.9	3
193	Assessing robot-assisted laparoscopic prostatectomy. <i>Lancet, The</i> , <b>2017</b> , 389, 799	40	5
192	The association of hypoalbuminemia with early perioperative outcomes - A comprehensive assessment across 16 major procedures. <i>American Journal of Surgery</i> , <b>2017</b> , 214, 871-883	2.7	28
191	Effect of Nonurothelial Histologic Variants on the Outcomes of Radical Cystectomy for Nonmetastatic Muscle-invasive Urinary Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , <b>2017</b> ,	3.3	9
190	Exploring exposure to Agent Orange and increased mortality due to bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2017</b> , 35, 627-632	2.8	2
189	The Use of Prostate Specific Antigen Screening in Purchased versus Direct Care Settings: Data from the TRICARE <sup>[]</sup> Military Database. <i>Journal of Urology</i> , <b>2017</b> , 198, 1295-1300	2.5	6
188	Caution with Use of the EPIC-50 Urinary Bother Scale: How Voiding Dysfunction Modifies its Performance. <i>Journal of Urology</i> , <b>2017</b> , 198, 1397-1403	2.5	3
187	Approach to the Patient with High-Risk Prostate Cancer. <i>Urologic Clinics of North America</i> , <b>2017</b> , 44, 635	- <b>6</b> .4 <sub>9</sub> 5	5
186	Investigating the possible causal role of coffee consumption with prostate cancer risk and progression using Mendelian randomization analysis. <i>International Journal of Cancer</i> , <b>2017</b> , 140, 322-325	<sub>8</sub> 7·5	13
185	Human vascular progenitor cells derived from renal arteries are endothelial-like and assist in the repair of injured renal capillary networks. <i>Kidney International</i> , <b>2017</b> , 91, 129-143	9.9	31
184	Alcohol consumption and prostate cancer incidence and progression: A Mendelian randomisation study. <i>International Journal of Cancer</i> , <b>2017</b> , 140, 75-85	7.5	22
183	Two Novel Susceptibility Loci for Prostate Cancer in Men of African Ancestry. <i>Journal of the National Cancer Institute</i> , <b>2017</b> , 109,	9.7	38
182	Antigen spread (AgS) after sipuleucel-T (sip-T): A cross-trial comparison of 4 sip-T clinical trials of patients (pts) with prostate cancer (PC) <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 143-143	2.2	1
181	Effectiveness of adjuvant chemotherapy after radical nephroureterectomy for locally advanced and/or positive regional lymph node upper tract urothelial carcinoma <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 305-305	2.2	1

# (2016-2017)

180	invasive bladder cancer (NMIBC): A population-based analysis <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 332-332	2.2	1
179	Androgen receptor-mediated downregulation of microRNA-221 and -222 in castration-resistant prostate cancer. <i>PLoS ONE</i> , <b>2017</b> , 12, e0184166	3.7	19
178	Adverse effects of ADT on cognitive function and dementia for men with prostate cancer: A meta-analysis and systematic review <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 150-150	2.2	1
177	Effect of decipher test on adjuvant treatment decision-making among men with high-risk pathology at radical prostatectomy: Results from a multicenter prospective PRO-IMPACT study <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 24-24	2.2	
176	Sipuleucel-T (sip-T) induced lytic CD8+ T cell responses to target antigens in men with hormone-sensitive and castration-resistant prostate cancer (CRPC) <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 162-162	2.2	
175	Cytokine profile of sipuleucel-T (sip-T) in differentiating reactivation of latent immunity from de novo immune responses <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 163-163	2.2	
174	Sipuleucel-T (sip-T) to induce cytolytic T lymphocyte (CTL) activity against target antigens in men with hormone-sensitive and castration-resistant prostate cancer (CRPC) <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 5046-5046	2.2	
173	SNP interaction pattern identifier (SIPI): an intensive search for SNP-SNP interaction patterns. <i>Bioinformatics</i> , <b>2017</b> , 33, 822-833	7.2	8
172	Adverse pathologic characteristics in the small renal mass: implications for active surveillance. <i>Canadian Journal of Urology</i> , <b>2017</b> , 24, 8759-8764	0.8	6
171	Rare Variation in TET2 Is Associated with Clinically Relevant Prostate Carcinoma in African Americans. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2016</b> , 25, 1456-1463	4	14
170	Risk of Small Bowel Obstruction After Robot-Assisted vs Open Radical Prostatectomy. <i>Journal of Endourology</i> , <b>2016</b> , 30, 1291-1295	2.7	4
169	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. <i>Cancer Discovery</i> , <b>2016</b> , 6, 1052-6	5 <del>7</del> 4·4	104
168	Atlas of prostate cancer heritability in European and African-American men pinpoints tissue-specific regulation. <i>Nature Communications</i> , <b>2016</b> , 7, 10979	17.4	37
167	Pubertal development and prostate cancer risk: Mendelian randomization study in a population-based cohort. <i>BMC Medicine</i> , <b>2016</b> , 14, 66	11.4	29
166	Surgeon and Hospital Level Variation in the Costs of Robot-Assisted Radical Prostatectomy. <i>Journal of Urology</i> , <b>2016</b> , 196, 1090-5	2.5	29
165	Efficacy of High-Intensity Local Treatment for Metastatic Urothelial Carcinoma of the Bladder: A Propensity Score-Weighted Analysis From the National Cancer Data Base. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 3529-3536	2.2	47
164	Baseline Prostate-Specific Antigen Levels in Midlife Predict Lethal Prostate Cancer. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 2705-11	2.2	48
163	The Contemporary Incidence and Sequelae of Rhabdomyolysis Following Extirpative Renal Surgery: A Population Based Analysis. <i>Journal of Urology</i> , <b>2016</b> , 195, 399-405	2.5	5

162	Causes of hospital readmissions after urologic cancer surgery. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2016</b> , 34, 236.e1-11	2.8	29
161	Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array. <i>British Journal of Cancer</i> , <b>2016</b> , 114, 945-52	8.7	13
160	Racial Differences in the Surgical Care of Medicare Beneficiaries With Localized Prostate Cancer. <i>JAMA Oncology</i> , <b>2016</b> , 2, 85-93	13.4	61
159	The impact of histological variants on bladder cancer survival: A population-based analysis <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 458-458	2.2	1
158	Sipuleucel-T (sip-T)[Induced proliferative CD8+ T-cell responses to immunizing and secondary antigens <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 165-165	2.2	1
157	Sipuleucel-T (sip-T)Induced lytic CD8+ T cell responses to target antigens in men with hormone-sensitive and castration-resistant prostate cancer (CRPC) <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, e23116-e23116	2.2	
156	Effect of a genomic classifier on adjuvant treatment decision-making among patients with high-risk pathology at radical prostatectomy: Results from the multicenter prospective PRO-IMPACT study <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 5053-5053	2.2	
155	Effect of a genomic classifier on treatment decision-making among patients with biochemical recurrence after radical prostatectomy: Results from the multicenter prospective PRO-IMPACT study <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, e16558-e16558	2.2	
154	Suicide and accidental deaths among patients with non-metastatic prostate cancer. <i>BJU International</i> , <b>2016</b> , 118, 286-97	5.6	30
153	Genetic variants in cell cycle control pathway confer susceptibility to aggressive prostate carcinoma. <i>Prostate</i> , <b>2016</b> , 76, 479-90	4.2	9
152	Dose-dependent effect of androgen deprivation therapy for localized prostate cancer on adverse cardiac events. <i>BJU International</i> , <b>2016</b> , 118, 221-9	5.6	16
151	NCCN Guidelines Insights: Bladder Cancer, Version 2.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2016</b> , 14, 1213-1224	7.3	73
150	PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. <i>Journal of Medical Genetics</i> , <b>2016</b> , 53, 800-811	5.8	121
149	Complications Following Common Inpatient Urological Procedures: Temporal Trend Analysis from 2000 to 2010. <i>European Urology Focus</i> , <b>2016</b> , 2, 3-9	5.1	5
148	The Effect of Resident Involvement on Surgical Outcomes for Common Urologic Procedures: A Case Study of Uni- and Bilateral Hydrocele Repair. <i>Urology</i> , <b>2016</b> , 94, 70-6	1.6	10
147	Trends of acute kidney injury after radical or partial nephrectomy for renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2016</b> , 34, 293.e1-293.e10	2.8	36
146	Determinants of cancer screening in Asian-Americans. Cancer Causes and Control, 2016, 27, 989-98	2.8	19
145	Meat, Fish, Poultry, and Egg Intake at Diagnosis and Risk of Prostate Cancer Progression. <i>Cancer Prevention Research</i> , <b>2016</b> , 9, 933-941	3.2	14

144	Polyunsaturated fatty acids and prostate cancer risk: a Mendelian randomisation analysis from the PRACTICAL consortium. <i>British Journal of Cancer</i> , <b>2016</b> , 115, 624-31	8.7	21
143	Assessing the role of insulin-like growth factors and binding proteins in prostate cancer using Mendelian randomization: Genetic variants as instruments for circulating levels. <i>International Journal of Cancer</i> , <b>2016</b> , 139, 1520-33	7.5	18
142	Blood lipids and prostate cancer: a Mendelian randomization analysis. <i>Cancer Medicine</i> , <b>2016</b> , 5, 1125-3	64.8	45
141	Nomogram Predicting Prostate Cancer-specific Mortality for Men with Biochemical Recurrence After Radical Prostatectomy. <i>European Urology</i> , <b>2015</b> , 67, 1160-1167	10.2	133
140	Words of wisdom. Re: Enzalutamide in metastatic prostate cancer before chemotherapy. <i>European Urology</i> , <b>2015</b> , 67, 174	10.2	2
139	A Comparison of 30-Day Perioperative Outcomes in Open Versus Minimally Invasive Nephroureterectomy for Upper Tract Urothelial Carcinoma: Analysis of 896 Patients from the American College of Surgeons-National Surgical Quality Improvement Program Database. <i>Journal</i>	2.7	18
138	Preventable mortality after common urological surgery: failing to rescue?. <i>BJU International</i> , <b>2015</b> , 115, 666-74	5.6	10
137	The impact of robotic surgery on the surgical management of prostate cancer in the USA. <i>BJU International</i> , <b>2015</b> , 115, 929-36	5.6	65
136	The impact of resident involvement in male one-stage anterior urethroplasties. <i>Urology</i> , <b>2015</b> , 85, 937-	<b>41</b> .6	17
135	New trends in the surgical management of invasive bladder cancer. <i>Hematology/Oncology Clinics of North America</i> , <b>2015</b> , 29, 253-69, viii	3.1	9
134	Effect of preoperative angina pectoris on cardiac outcomes in patients with previous myocardial infarction undergoing major noncardiac surgery (data from ACS-NSQIP). <i>American Journal of Cardiology</i> , <b>2015</b> , 115, 1080-4	3	11
133	Comparison of 30-day perioperative outcomes in adults undergoing open versus minimally invasive pyeloplasty for ureteropelvic junction obstruction: analysis of 593 patients in a prospective national database. <i>World Journal of Urology</i> , <b>2015</b> , 33, 2107-13	4	9
132	The Effect of Body Mass Index on Perioperative Outcomes After Major Surgery: Results from the National Surgical Quality Improvement Program (ACS-NSQIP) 2005-2011. <i>World Journal of Surgery</i> , <b>2015</b> , 39, 2376-85	3.3	47
131	The effects of height and BMI on prostate cancer incidence and mortality: a Mendelian randomization study in 20,848 cases and 20,214 controls from the PRACTICAL consortium. <i>Cancer Causes and Control</i> , <b>2015</b> , 26, 1603-16	2.8	56
130	Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans. <i>Human Molecular Genetics</i> , <b>2015</b> , 24, 5589-602	5.6	54
129	The Effect of Resident Involvement on Perioperative Outcomes in Transurethral Urologic Surgeries. Journal of Surgical Education, <b>2015</b> , 72, 1018-25	3.4	27
128	Contemporary nationwide patterns of self-reported prostate-specific antigen screening in US veterans. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2015</b> , 33, 503.e7-15	2.8	7
127	Genome-wide association study of prostate cancer-specific survival. <i>Cancer Epidemiology</i> Biomarkers and Prevention, <b>2015</b> , 24, 1796-800	4	23

126	Temporal trends in receipt of adequate lymphadenectomy in bladder cancer 1988 to 2010. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2015</b> , 33, 504.e9-17	2.8	19
125	Calcium intake, polymorphisms of the calcium-sensing receptor, and recurrent/aggressive prostate cancer. <i>Cancer Causes and Control</i> , <b>2015</b> , 26, 1751-9	2.8	5
124	The burden of skeletal-related events in patients with prostate cancer and bone metastasis. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2015</b> , 33, 17.e9-17.e18	2.8	20
123	Minimally important difference for the Expanded Prostate Cancer Index Composite Short Form. <i>Urology</i> , <b>2015</b> , 85, 101-5	1.6	161
122	Impact of surgeon volume on the morbidity and costs of radical cystectomy in the USA: a contemporary population-based analysis. <i>BJU International</i> , <b>2015</b> , 115, 713-21	5.6	60
121	Racial Disparities in End-of-Life Care Among Patients With Prostate Cancer: A Population-Based Study. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2015</b> , 13, 1131-8	7.3	30
120	Racial/Ethnic Disparities in Perioperative Outcomes of Major Procedures: Results From the National Surgical Quality Improvement Program. <i>Annals of Surgery</i> , <b>2015</b> , 262, 955-64	7.8	69
119	An evaluation of the Rweekend effectPin patients admitted with metastatic prostate cancer. <i>BJU International</i> , <b>2015</b> , 116, 911-9	5.6	7
118	Prediction of individual genetic risk to prostate cancer using a polygenic score. <i>Prostate</i> , <b>2015</b> , 75, 1467	-74	43
117	Treatment Decision Making in Patients with Bladder Cancer. <i>Bladder Cancer</i> , <b>2015</b> , 1, 151-158	1	16
116	Impact of smoking on perioperative outcomes after major surgery. <i>American Journal of Surgery</i> , <b>2015</b> , 210, 221-229.e6	2.7	51
115	Patterns of Declining Use and the Adverse Effect of Primary Androgen Deprivation on All-cause Mortality in Elderly Men with Prostate Cancer. <i>European Urology</i> , <b>2015</b> , 68, 32-9	10.2	35
114	Urolithiasis and urinary tract infection among patients with inflammatory bowel disease: a review of US emergency department visits between 2006 and 2009. <i>Urology</i> , <b>2015</b> , 85, 764-70	1.6	12
113	Are biochemical recurrence outcomes similar after radical prostatectomy and radiation therapy? Analysis of prostate cancer-specific mortality by nomogram-predicted risks of biochemical recurrence. <i>European Urology</i> , <b>2015</b> , 67, 204-9	10.2	34
112	Transperineal in-bore 3-T MR imaging-guided prostate biopsy: a prospective clinical observational study. <i>Radiology</i> , <b>2015</b> , 274, 170-80	20.5	65
111	The RAZOR (randomized open vs robotic cystectomy) trial: study design and trial update. <i>BJU International</i> , <b>2015</b> , 115, 198-205	5.6	68
110	Burden of hospital admissions and utilization of hospice care in metastatic prostate cancer patients. <i>Urology</i> , <b>2015</b> , 85, 343-9	1.6	14
109	Defining a standard set of patient-centered outcomes for men with localized prostate cancer. <i>European Urology</i> , <b>2015</b> , 67, 460-7	10.2	136

108	A Large-Scale Analysis of Genetic Variants within Putative miRNA Binding Sites in Prostate Cancer. <i>Cancer Discovery</i> , <b>2015</b> , 5, 368-79	24.4	41
107	Generalizability of established prostate cancer risk variants in men of African ancestry. <i>International Journal of Cancer</i> , <b>2015</b> , 136, 1210-7	7.5	51
106	Immune responses and clinical outcomes in STAND, a randomized phase 2 study evaluating optimal sequencing of sipuleucel-T (sip-T) and androgen deprivation therapy (ADT) in biochemically-recurrent prostate cancer (BRPC) after local therapy failure <i>Journal of Clinical</i>	2.2	1
105	Antigen-specific immune responses through 24 months in the STAND trial: A randomized phase 2 study evaluating optimal sequencing of sipuleucel-T (sip-T) and androgen deprivation therapy (ADT) in biochemically-recurrent prostate cancer (BRPC) <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 171-17	2.2 1	3
104	Optimal timing of sipuleucel-T treatment in metastatic castration-resistant prostate cancer. <i>Canadian Journal of Urology</i> , <b>2015</b> , 22, 8048-55	0.8	7
103	Analysis of intracorporeal compared with extracorporeal urinary diversion after robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium. <i>European Urology</i> , <b>2014</b> , 65, 340-7	10.2	196
102	Prostate cancer (PCa) risk variants and risk of fatal PCa in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. <i>European Urology</i> , <b>2014</b> , 65, 1069-75	10.2	58
101	Cytoreductive nephrectomy in patients with metastatic non-clear-cell renal cell carcinoma (RCC). <i>BJU International</i> , <b>2014</b> , 113, E67-74	5.6	43
100	Efficacy of robot-assisted radical cystectomy (RARC) in advanced bladder cancer: results from the International Radical Cystectomy Consortium (IRCC). <i>BJU International</i> , <b>2014</b> , 114, 98-103	5.6	13
99	Mental health outcomes in elderly men with prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2014</b> , 32, 1333-40	2.8	39
98	Morbidity and mortality after benign prostatic hyperplasia surgery: data from the American College of Surgeons national surgical quality improvement program. <i>Journal of Endourology</i> , <b>2014</b> , 28, 831-40	2.7	55
97	Comparative effectiveness of robot-assisted and open radical prostatectomy in the postdissemination era. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 1419-26	2.2	140
96	Chronic kidney disease and perioperative outcomes in urological oncological surgery. <i>International Journal of Urology</i> , <b>2014</b> , 21, 1245-52	2.3	6
95	A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. <i>Nature Genetics</i> , <b>2014</b> , 46, 1103-9	36.3	331
94	Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 1889-94	2.2	177
93	The health care burden of skeletal related events in patients with renal cell carcinoma and bone metastasis. <i>Journal of Urology</i> , <b>2014</b> , 191, 1678-84	2.5	16
92	Short-term perioperative outcomes of patients treated with radical cystectomy for bladder cancer included in the National Surgical Quality Improvement Program (NSQIP) database. <i>Canadian Urological Association Journal</i> , <b>2014</b> , 8, E681-7	1.2	44
91	Fine-mapping the HOXB region detects common variants tagging a rare coding allele: evidence for synthetic association in prostate cancer. <i>PLoS Genetics</i> , <b>2014</b> , 10, e1004129	6	30

90	Predictors of 30-day acute kidney injury following radical and partial nephrectomy for renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2014</b> , 32, 1259-66	2.8	42
89	Effect of minimally invasive surgery on the risk for surgical site infections: results from the National Surgical Quality Improvement Program (NSQIP) Database. <i>JAMA Surgery</i> , <b>2014</b> , 149, 1039-44	5.4	77
88	Contemporary nationwide patterns of self-reported prostate-specific antigen screening. <i>JAMA Internal Medicine</i> , <b>2014</b> , 174, 1839-41	11.5	29
87	The impact of resident involvement in minimally-invasive urologic oncology procedures. <i>Canadian Urological Association Journal</i> , <b>2014</b> , 8, 334-40	1.2	38
86	Clinical-pathologic stage discrepancy in bladder cancer patients treated with radical cystectomy: results from the national cancer data base. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2014</b> , 88, 1048-56	4	57
85	Propensity-matched comparison of morbidity and costs of open and robot-assisted radical cystectomies: a contemporary population-based analysis in the United States. <i>European Urology</i> , <b>2014</b> , 66, 569-76	10.2	175
84	Reply to Michael Froehner® letter to the editor re: Kenneth G. Nepple, Andrew J. Stephenson, Dorina Kallogjeri, et al. Mortality after prostate cancer treatment with radical prostatectomy, external-beam radiation therapy, or brachytherapy in men without comorbidity. Eur Urol	10.2	
83	2013;64:372-8. European Urology, <b>2014</b> , 65, e42 A guide for clinicians in the evaluation of emerging molecular diagnostics for newly diagnosed prostate cancer. <i>Reviews in Urology</i> , <b>2014</b> , 16, 172-80	1	19
82	Readmissions after major urologic cancer surgery. Canadian Journal of Urology, 2014, 21, 7537-46	0.8	24
81	Who should be included in a clinical trial of screening for bladder cancer?: a decision analysis of data from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. <i>Cancer</i> , <b>2013</b> , 119, 143-9	6.4	27
80	Reply from authors re: Manfred P. Wirth, Johannes Huber. What really matters is rarely measured: outcome of routine care and patient-reported outcomes. Eur Urol 2013;64:58-9: robot-assisted versus open radical cystectomy: beating a dead horse. <i>European Urology</i> , <b>2013</b> , 64, 60-1	10.2	
79	The 2011-2016 Transdisciplinary Research on Energetics and Cancer (TREC) initiative: rationale and design. <i>Cancer Causes and Control</i> , <b>2013</b> , 24, 695-704	2.8	42
78	Contemporary role of systematic prostate biopsies: indications, techniques, and implications for patient care. <i>European Urology</i> , <b>2013</b> , 63, 214-30	10.2	163
77	Complications after robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium. <i>European Urology</i> , <b>2013</b> , 64, 52-7	10.2	160
76	Early oncologic outcomes of robotic vs. open radical cystectomy for urothelial cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2013</b> , 31, 894-8	2.8	41
75	Mortality after prostate cancer treatment with radical prostatectomy, external-beam radiation therapy, or brachytherapy in men without comorbidity. <i>European Urology</i> , <b>2013</b> , 64, 372-8	10.2	53
74	Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. <i>Nature Genetics</i> , <b>2013</b> , 45, 385-91, 391e1-2	36.3	413
73	Constitutive Etatenin activation induces male-specific tumorigenesis in the bladder urothelium. <i>Cancer Research</i> , <b>2013</b> , 73, 5914-25	10.1	40

# (2011-2013)

72	Fine-mapping identifies multiple prostate cancer risk loci at 5p15, one of which associates with TERT expression. <i>Human Molecular Genetics</i> , <b>2013</b> , 22, 2520-8	5.6	88
71	11C-acetate PET/CT before radical prostatectomy: nodal staging and treatment failure prediction. <i>Journal of Nuclear Medicine</i> , <b>2013</b> , 54, 699-706	8.9	70
70	Predicting risk of bladder cancer using clinical and demographic information from prostate, lung, colorectal, and ovarian cancer screening trial participants. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2013</b> , 22, 2241-9	4	7
69	Impact of surgeon and volume on extended lymphadenectomy at the time of robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium (IRCC). <i>BJU International</i> , <b>2013</b> , 111, 1075-80	5.6	42
68	Adjuvant leuprolide with or without docetaxel in patients with high-risk prostate cancer after radical prostatectomy (TAX-3501): important lessons for future trials. <i>Cancer</i> , <b>2013</b> , 119, 3610-8	6.4	38
67	A randomized phase II study evaluating the optimal sequencing of sipuleucel-T and androgen deprivation therapy (ADT) in biochemically recurrent prostate cancer (BRPC): Immune results <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 5016-5016	2.2	4
66	Randomized phase II trial evaluating the optimal sequencing of sipuleucel-T and androgen-deprivation therapy (ADT) in patients (pts) with biochemically recurrent prostate cancer (BRPC) <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 34-34	2.2	6
65	Prospective evaluation of testosterone (T) recovery and PSA relapse following 18 months of androgen deprivation (ADT) after prostatectomy (RP): Results from the TAX-3501 trial <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 5023-5023	2.2	
64	Comparative analysis of outcomes and costs following open radical cystectomy versus robot-assisted laparoscopic radical cystectomy: results from the US Nationwide Inpatient Sample. <i>European Urology</i> , <b>2012</b> , 61, 1239-44	10.2	134
63	Ureteral injury in laparoscopic gynecologic surgery. Reviews in Obstetrics and Gynecology, <b>2012</b> , 5, 106-	-11	36
62			
	Ability of linear length of positive margin in radical prostatectomy specimens to predict biochemical recurrence. <i>Urology</i> , <b>2011</b> , 77, 1409-14	1.6	33
61		1.6	<ul><li>33</li><li>53</li></ul>
	Positive margin during partial nephrectomy: does cancer remain in the renal remnant?. <i>Urology</i> ,		
61	Positive margin during partial nephrectomy: does cancer remain in the renal remnant?. <i>Urology</i> , <b>2011</b> , 77, 1400-3	1.6	53
61	Positive margin during partial nephrectomy: does cancer remain in the renal remnant?. <i>Urology</i> , <b>2011</b> , 77, 1400-3  Indications and practice with androgen deprivation therapy. <i>Urology</i> , <b>2011</b> , 78, S478-81	1.6	53 3
61 60 59	Positive margin during partial nephrectomy: does cancer remain in the renal remnant?. <i>Urology</i> , <b>2011</b> , 77, 1400-3  Indications and practice with androgen deprivation therapy. <i>Urology</i> , <b>2011</b> , 78, S478-81  Targeting the androgen receptortheory and practice. <i>Urology</i> , <b>2011</b> , 78, S482-4  The role of lymphovascular space invasion in renal cell carcinoma as a prognostic marker of survival	1.6 1.6	<ul><li>53</li><li>3</li><li>5</li></ul>
61 60 59 58	Positive margin during partial nephrectomy: does cancer remain in the renal remnant?. <i>Urology</i> , <b>2011</b> , 77, 1400-3  Indications and practice with androgen deprivation therapy. <i>Urology</i> , <b>2011</b> , 78, S478-81  Targeting the androgen receptortheory and practice. <i>Urology</i> , <b>2011</b> , 78, S482-4  The role of lymphovascular space invasion in renal cell carcinoma as a prognostic marker of survival after curative resection. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2011</b> , 29, 738-44  Lymphadenectomy at the time of robot-assisted radical cystectomy: results from the International	1.6 1.6 1.6 2.8	<ul><li>53</li><li>3</li><li>5</li><li>27</li></ul>

54	Laparoscopic retroperitoneal lymph node dissection for low-stage cancer: a Washington University update. <i>Journal of Endourology</i> , <b>2011</b> , 25, 1753-7	2.7	12
53	Prostate cancer predisposition loci and risk of metastatic disease and prostate cancer recurrence. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 1075-81	12.9	37
52	Prediction of erectile function following treatment for prostate cancer. <i>JAMA - Journal of the American Medical Association</i> , <b>2011</b> , 306, 1205-14	27.4	213
51	Validation of genome-wide prostate cancer associations in men of African descent. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2011</b> , 20, 23-32	4	79
50	Does previous robot-assisted radical prostatectomy experience affect outcomes at robot-assisted radical cystectomy? Results from the International Robotic Cystectomy Consortium. <i>Urology</i> , <b>2010</b> , 76, 1111-6	1.6	42
49	The Gleason score of tumor at the margin in radical prostatectomy is predictive of biochemical recurrence. <i>American Journal of Surgical Pathology</i> , <b>2010</b> , 34, 994-1001	6.7	57
48	High-risk localized prostate cancer: role of radical prostatectomy. <i>Current Opinion in Urology</i> , <b>2010</b> , 20, 204-10	2.8	11
47	The learning curve of robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium. <i>European Urology</i> , <b>2010</b> , 58, 197-202	10.2	176
46	Reply from authors re: Urs E. Studer, Laurence Collette. Robot-assisted cystectomy: does it meet expectations? Eur Urol 2010;58:203-4. <i>European Urology</i> , <b>2010</b> , 58, 204-6	10.2	
45	Rebuttal to Dr. Wallner. <i>Brachytherapy</i> , <b>2010</b> , 9, 200-201	2.4	1
45 44	Rebuttal to Dr. Wallner. <i>Brachytherapy</i> , <b>2010</b> , 9, 200-201  Counterpoint: Prostate carcinoma treatment for the young patientThe case for radical prostatectomy. <i>Brachytherapy</i> , <b>2010</b> , 9, 195-8; discussion 199-201	2.4	1
	Counterpoint: Prostate carcinoma treatment for the young patientThe case for radical		
44	Counterpoint: Prostate carcinoma treatment for the young patientThe case for radical prostatectomy. <i>Brachytherapy</i> , <b>2010</b> , 9, 195-8; discussion 199-201  Association of CASP8 D302H polymorphism with reduced risk of aggressive prostate carcinoma.	2.4	1
44	Counterpoint: Prostate carcinoma treatment for the young patientThe case for radical prostatectomy. <i>Brachytherapy</i> , <b>2010</b> , 9, 195-8; discussion 199-201  Association of CASP8 D302H polymorphism with reduced risk of aggressive prostate carcinoma. <i>Prostate</i> , <b>2010</b> , 70, 646-53  Prospective study of [18F]fluorodeoxyglucose positron emission tomography/computed tomography for staging of muscle-invasive bladder carcinoma. <i>Journal of Clinical Oncology</i> , <b>2009</b> ,	2.4	1
44 43 42	Counterpoint: Prostate carcinoma treatment for the young patientThe case for radical prostatectomy. <i>Brachytherapy</i> , <b>2010</b> , 9, 195-8; discussion 199-201  Association of CASP8 D302H polymorphism with reduced risk of aggressive prostate carcinoma. <i>Prostate</i> , <b>2010</b> , 70, 646-53  Prospective study of [18F]fluorodeoxyglucose positron emission tomography/computed tomography for staging of muscle-invasive bladder carcinoma. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 4314-20  Prostate cancer risk associated loci in African Americans. <i>Cancer Epidemiology Biomarkers and</i>	2.4	1 15 178
44 43 42 41	Counterpoint: Prostate carcinoma treatment for the young patientThe case for radical prostatectomy. <i>Brachytherapy</i> , <b>2010</b> , 9, 195-8; discussion 199-201  Association of CASP8 D302H polymorphism with reduced risk of aggressive prostate carcinoma. <i>Prostate</i> , <b>2010</b> , 70, 646-53  Prospective study of [18F]fluorodeoxyglucose positron emission tomography/computed tomography for staging of muscle-invasive bladder carcinoma. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 4314-20  Prostate cancer risk associated loci in African Americans. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2009</b> , 18, 2145-9  Vitamin D-related genes, serum vitamin D concentrations and prostate cancer risk. <i>Carcinogenesis</i> ,	2.4 4.2 2.2	1 15 178 53
44 43 42 41 40	Counterpoint: Prostate carcinoma treatment for the young patientThe case for radical prostatectomy. <i>Brachytherapy</i> , <b>2010</b> , 9, 195-8; discussion 199-201  Association of CASP8 D302H polymorphism with reduced risk of aggressive prostate carcinoma. <i>Prostate</i> , <b>2010</b> , 70, 646-53  Prospective study of [18F]fluorodeoxyglucose positron emission tomography/computed tomography for staging of muscle-invasive bladder carcinoma. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 4314-20  Prostate cancer risk associated loci in African Americans. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2009</b> , 18, 2145-9  Vitamin D-related genes, serum vitamin D concentrations and prostate cancer risk. <i>Carcinogenesis</i> , <b>2009</b> , 30, 769-76	2.4 4.2 2.2 4 4.6	1 15 178 53

# (2005-2008)

36	Variation in KLK genes, prostate-specific antigen and risk of prostate cancer. <i>Nature Genetics</i> , <b>2008</b> , 40, 1032-4; author reply 1035-6	36.3	74
35	Prognostic impact of comorbidity in patients with bladder cancer. European Urology, 2008, 53, 581-9	10.2	36
34	Impact of comorbidity on overall survival in patients surgically treated for renal cell carcinoma. <i>Urology</i> , <b>2008</b> , 72, 359-63	1.6	36
33	Quality of life and satisfaction with outcome among prostate-cancer survivors. <i>New England Journal of Medicine</i> , <b>2008</b> , 358, 1250-61	59.2	1697
32	Association between polymorphisms in cell cycle genes and advanced prostate carcinoma. <i>Prostate</i> , <b>2008</b> , 68, 1179-86	4.2	20
31	Evaluation of a novel precision template-guided biopsy system for detecting prostate cancer. <i>BJU International</i> , <b>2008</b> , 102, 546-50	5.6	36
30	SnoRNA U50 is a candidate tumor-suppressor gene at 6q14.3 with a mutation associated with clinically significant prostate cancer. <i>Human Molecular Genetics</i> , <b>2008</b> , 17, 1031-42	5.6	153
29	Prostate-specific antigen density predicts adverse pathology and increased risk of biochemical failure. <i>Urology</i> , <b>2007</b> , 69, 1121-7	1.6	43
28	The use and abuse of data: nomograms and talking to patients about clinical medicine. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2007</b> , 25, 333-7	2.8	8
27	Genome-wide association study of prostate cancer identifies a second risk locus at 8q24: Yeager M, Orr N, Hayes RB, Jacobs KB, Kraft P, Wacholder S, Minichiello MJ, Fearnhead P, Yu K, Chatterjee N, Wang Z, Welch R, Staats BJ, Calle EE, Feigelson HS, Thun MJ, Rodriguez C, Albanes D, Virtamo J,	2.8	1
26	TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2007</b> , 25, 448-449	2.8	3
25	Integrative molecular concept modeling of prostate cancer progression. <i>Urologic Oncology:</i> Seminars and Original Investigations, <b>2007</b> , 25, 449-450	2.8	
24	An infectious retrovirus susceptible to an IFN antiviral pathway from human prostate tumors: Dong B, Kim S, Hong S, Das Gupta J, Malathi K, Klein EA, Ganem D, Derisi JL, Chow SA, Silverman RH, Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2007</b> , 25, 450	2.8	
23	Trends in nephron-sparing surgery for renal neoplasia. <i>Urology</i> , <b>2006</b> , 68, 732-6	1.6	12
22	Single nucleotide polymorphisms: early diagnosis and risk assessment in genitourinary malignancy. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2006</b> , 24, 224-30	2.8	
21	Association of hereditary prostate cancer gene polymorphic variants with sporadic aggressive prostate carcinoma. <i>Prostate</i> , <b>2006</b> , 66, 49-56	4.2	36
20	An interdisciplinary approach to treating prostate cancer. <i>Urology</i> , <b>2005</b> , 65, 13-8	1.6	11
19	Laparoscopic renal surgery and the risk of rhabdomyolysis: diagnosis and treatment. <i>Urology</i> , <b>2005</b> , 66, 29-35	1.6	78

18	Parenchymal imaging adds diagnostic utility in evaluating haematuria. <i>BJU International</i> , <b>2005</b> , 95, 64-7	5.6	2
17	Expression mapping at 12p12-13 in advanced prostate carcinoma. <i>International Journal of Cancer</i> , <b>2004</b> , 109, 668-72	7.5	20
16	Xq27-28 deletions in prostate carcinoma. <i>Genes Chromosomes and Cancer</i> , <b>2003</b> , 37, 381-8	5	11
15	Hemostatic laparoscopic partial nephrectomy assisted by a water-cooled, high-density, monopolar device without renal vascular control. <i>Urology</i> , <b>2003</b> , 61, 906-9	1.6	50
14	Surgical treatment of renal neoplasia: evolving toward a laparoscopic standard of care. <i>Urology</i> , <b>2003</b> , 62, 821-6	1.6	57
13	Modified renal morcellation for renal cell carcinoma: laboratory experience and early clinical application. <i>Urology</i> , <b>2003</b> , 62, 632-4; discussion 635	1.6	27
12	11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse. <i>Journal of Nuclear Medicine</i> , <b>2003</b> , 44, 549-55	8.9	183
11	CDKN1A and CDKN1B polymorphisms and risk of advanced prostate carcinoma. <i>Cancer Research</i> , <b>2003</b> , 63, 2033-6	10.1	60
10	Patterns of multiple recurrences of superficial (Ta/T1) transitional cell carcinoma of bladder and effects of clinicopathologic and biochemical factors. <i>Cancer</i> , <b>2002</b> , 95, 1239-46	6.4	24
9	Mutational analysis of ETV6 in prostate carcinoma. <i>Prostate</i> , <b>2002</b> , 52, 305-10	4.2	16
8	Laparoscopic partial nephrectomy with a novel electrosurgical snare in a porcine model. <i>Journal of Endourology</i> , <b>2002</b> , 16, 673-9	2.7	13
7	Methylation and mutational analysis of p27(kip1) in prostate carcinoma. <i>Prostate</i> , <b>2001</b> , 48, 248-53	4.2	33
6	G(1)/S cell cycle proteins as markers of aggressive prostate carcinoma. <i>Urology</i> , <b>2000</b> , 55, 316-22	1.6	13
5	Prostatic Diseases. <i>Journal of Urology</i> , <b>2000</b> , 163, 2054-2054	2.5	
4	Familial calcium stone disease: TaqI polymorphism and the vitamin D receptor. <i>Journal of Endourology</i> , <b>1999</b> , 13, 313-6	2.7	56
3	PROGNOSTIC FEATURES OF TERATOMAS WITH MALIGNANT TRANSFORMATION: A CLINICOPATHOLOGICAL STUDY OF 21 CASES. <i>Journal of Urology</i> , <b>1998</b> , 159, 859-863	2.5	113
2	Constitutive expression of high levels of prostate-specific antigen in the absence of prostate carcinoma. <i>Urology</i> , <b>1996</b> , 48, 741-6	1.6	7